-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, VgW3Cu4HzJsTssWZuSUDdbcPME5nmUr39kFvVjh18TCQqklWU29QUSYIQYgE+kP+ hmt4Vs/UBoNcEw38HDky2w== 0000950124-06-001017.txt : 20060307 0000950124-06-001017.hdr.sgml : 20060307 20060307163033 ACCESSION NUMBER: 0000950124-06-001017 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060303 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20060307 DATE AS OF CHANGE: 20060307 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HELIX BIOMEDIX INC CENTRAL INDEX KEY: 0000831749 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 912099117 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 033-20897 FILM NUMBER: 06670481 BUSINESS ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 BUSINESS PHONE: 425 402 8400 MAIL ADDRESS: STREET 1: 22122 20TH AVE SE CITY: BOTHELL STATE: WA ZIP: 98021 FORMER COMPANY: FORMER CONFORMED NAME: CARTEL ACQUISITIONS INC DATE OF NAME CHANGE: 19890718 FORMER COMPANY: FORMER CONFORMED NAME: CARIBBEAN ACQUISTIONS INC DATE OF NAME CHANGE: 19880725 8-K 1 v18243e8vk.htm FORM 8-K e8vk
 

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 3, 2006
 
HELIX BIOMEDIX, INC.
(Exact name of registrant as specified in its charter)
 
         
DELAWARE

(State or other jurisdiction

of incorporation or organization) 		  033-20897-D

(Commission File Number) 		  91-2099117

(IRS Employer

Identification No.)
22122 20th Avenue S.E., Suite 148
Bothell, Washington 98021
(425) 402-8400
(Address and telephone number of registrant’s principal executive offices)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

Item 3.02 Unregistered Sales of Equity Securities.
On March 3, 2006, Helix BioMedix, Inc. (the “Company”) consummated the sale of an aggregate of 2,383,000 shares of its Common Stock to 13 accredited investors at a purchase price of $1.00 per share for an aggregate purchase price of $2,383,000 along with warrants to purchase an additional 238,000 shares of its Common Stock at an exercise price of $1.00 per share. The warrants are immediately exercisable and expire on March 3, 2011. This sale was exempt from registration pursuant to Rule 506 of Regulation D under Section 4(2) of the Securities Act.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
         
  HELIX BIOMEDIX, INC.
 		  
Dated: March 7, 2006  By:   /s/ R. Stephen Beatty    
    R. Stephen Beatty   
    President and Chief Executive Officer   
 

 

-----END PRIVACY-ENHANCED MESSAGE-----